(NYSE:FCN), WASHINGTON, Feb. 04, 2026 (GLOBE NEWSWIRE) — FTI Consulting, Inc. (NYSE: FCN) today announced the appointment of Jane Wanklyn as a Senior Managing Director in the Business Transformation practice within the firm's Corporate Finance & Restructuring segment. Ms. Wanklyn, who is based in Chicago, joins with more than two decades of experience specializing in […]
(NASDAQ:DFLI),(NASDAQ:DFLIW), RENO, Nev., Feb. 04, 2026 (GLOBE NEWSWIRE) — Dragonfly Energy Holdings Corp. (Nasdaq: DFLI) (“Dragonfly Energy” or the “Company”), an industry leader in energy storage and battery technology and maker of Battle Born Batteries(R), won both the Sustainable Innovation Award and the Sustainable Product Award at the 2026 SEAL (Sustainability, Environmental Achievement, Leadership) Business
(NYSE:BFH), COLUMBUS, Ohio, Feb. 04, 2026 (GLOBE NEWSWIRE) — Bread Financial(R) Holdings, Inc. (NYSE: BFH), a tech-forward financial services company that provides simple, personalized payment, lending, and saving solutions, today announced the company's participation in the UBS Financial Services Conference on Wednesday, February 11. Bread Financial EVP and Chief Financial Officer Perry Beberman will participate
'Think Mortgage Calculator, But for Lung Cancer Risk': A More User-Friendly Self-Serve Tool Gives Canadians and Healthcare Providers a Clearer Starting Point A simple online tool offered by Lung Health Foundation helps people understand their potential lung cancer risk – no medical knowledge, paperwork or special access required GlobeNewswire February 04, 2026 TORONTO, Feb. 04,
Zevra Therapeutics Presents Positive New Real-World Data on MIPLYFFA(R) in Patients with Neimann-Pick Disease Type C (NPC) at the 22nd Annual WORLDSymposium(TM) Real-world and clinical trial data underscore long-term safety and effectiveness in pediatric and adult NPC patients GlobeNewswire February 04, 2026 CELEBRATION, Fla., Feb. 04, 2026 (GLOBE NEWSWIRE) — Zevra Therapeutics, Inc. (NasdaqGS: ZVRA)
Nature Medicine Publishes Results from the Pivotal DEVOTE Study of High-Dose Regimen of Nusinersen in Spinal Muscular Atrophy GlobeNewswire February 04, 2026 Findings from DEVOTE support clinical benefits of the high-dose regimen of nusinersen (50 mg and 28 mg) in both treatment-naive individuals and those previously treated with 12 mg nusinersen The high-dose regimen of
FirstService Reports Fourth Quarter and Full Year Results GlobeNewswire February 04, 2026 Delivers Strong Consolidated Annual Earnings Operating highlights: Three months ended Year ended December 31 December 31 2025 2024 2025 2024 Revenues (millions) $ 1,383.4 $ 1,365.3 $ 5,497.5 $ 5,216.9 Adjusted EBITDA (millions) (note 1) 137.6 137.9 562.8 513.7 Adjusted EPS (note 2)
SAGA Metals Achieves 100% Drilling Success in 2025–Reports Final Assays from Trapper South at Radar Critical Minerals Project in Labrador –Exceptional grades of Titanium, Vanadium and Iron in all 15 drill holes completed in 2025, bookending a 16+ km oxide strike length– GlobeNewswire February 04, 2026 VANCOUVER, British Columbia, Feb. 04, 2026 (GLOBE NEWSWIRE) —
BullFrog AI to Unveil New Precision AI Capability GlobeNewswire February 04, 2026 New capabilities to be launched on March 25 Unique technology bolsters BullFrog AI's end-to-end AI intelligence workflow with a scenario-based decision engine Advances current AI decision tools by clearly defining clinical trial strategies and building diversified, risk-balanced R&D portfolios GAITHERSBURG, Md., Feb. 04,
Spur Therapeutics Presents New Phase 1/2 Data on Its Gene Therapy Candidate in Gaucher Disease at 22nd Annual WORLDSymposium(TM) GlobeNewswire February 04, 2026 Two-year follow-up data demonstrate sustained benefit, including improvements in pain, fatigue and bone health, following single low dose of avigbagene parvec (FLT201) Robust improvements in lyso-Gb1, a surrogate biomarker for potential accelerated